MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Breast Cancer Treatment Studies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,781 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,781 works in the cohort · of 4,299,418page 2 of 56

Labels cover 13 of 2,781 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,781 of 2,781 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr +27 more
2017· article· en· Journal of the National Comprehensive Cancer Network· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
542
citations
afffundno abstractunlabeled
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Michael Gnant, Martin Filipits, Richard Greil, Herbert Stoeger, Margaretha Rudas, Zsuzsanna Bagó-Horváth +18 more
2013· article· en· Annals of Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
399
citations
affno abstractunlabeled
Volumetric Modulated Arc Therapy Improves Dosimetry and Reduces Treatment Time Compared to Conventional Intensity-Modulated Radiotherapy for Locoregional Radiotherapy of Left-Sided Breast Cancer and Internal Mammary Nodes
C. Popescu, Ivo A. Olivotto, Wayne Beckham, W. Ansbacher, Sergei Zavgorodni, Richard Shaffer +2 more
2009· article· en· International Journal of Radiation Oncology*Biology*Physics· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
361
citations
fundno affunlabeled
Modeling precision treatment of breast cancer
Anneleen Daemen, Obi L. Griffith, Laura M. Heiser, Nicholas J. Wang, Oana M. Enache, Zachary Sanborn +21 more
2013· article· en· Genome biology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
318
citations
affunlabeled
Past, Present, and Future Challenges in Breast Cancer Treatment
George W. Sledge, Eleftherios P. Mamounas, Gabriel N. Hortobágyi, Harold J. Burstein, Pamela J. Goodwin, Antonio C. Wolff
2014· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
275
citations
affno abstractunlabeled
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
C. Jillian Tsai, Jonathan T. Yang, Narek Shaverdian, Juber Patel, Annemarie F. Shepherd, Juliana Eng +40 more
2023· article· en· The Lancet· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
255
citations

How this was built: Screen · Findings · About